tions as well as the development and management of strategic alliances for the company. He has led licensing efforts which have resulted in licensing dozens of new technologies that have been developed into new clinical assays. Dr. Conti joined Quest Diagnostics in 2006. Prior to joining the company, he was Vice President, Business Development, for Becton Dickinson. Dr. Conti started his career at Union Carbide as a scientist engaged in catalysis research for their plastics division. Dr. Conti is a graduate of Notre Dame with a bachelor’s degree in chemistry. He received his Ph.D. in chemistry from the University of Florida and his M.B.A. from the Wharton School. Additionally, Dr. Conti is an Overseas Fellow of the Royal Society of Medicine.
Russel K. Enns, Ph.D., is the Chief Regulatory Officer of Cepheid overseeing staff and departments in Regulatory, Clinical and Government Affairs and Quality Systems and Compliance. He has been at Cepheid since June 2003. From 2001 to 2003 he was Divisional Vice President of Regulatory and Clinical Affairs, Quality Systems and Medical Reimbursement at Vysis (wholly owned by Abbott Laboratories), a genomic disease management company. Prior to the Abbott acquisition he served the same functions as above since 1995. Before joining Vysis, he was Vice President, Technical Affairs of MicroProbe Corporation, from 1992 to 1995. MicroProbe was sold to Becton Dickinson in 1995. Before joining MicroProbe, he held various positions at Gen-Probe, Inc. (a biotechnology diagnostic company), in order of Director of Product Development, Clinical Programs, and Technical Affairs from 1984 to 1992. Dr. Enns was the Director of Cell Biology R&D at Alpha Therapeutics Corporation from 1979 to 1984. From 1975 to 1979 he was a Senior Research Biochemist at Monsanto Corporation. He received his Ph.D. in biochemistry from the University of California, Davis, in 1976. He was a national foundation lecturer for ASM from 1988 to 1989. From 2005 to 2011 he served on the Clinical and Laboratory Standards Institute Board of Directors, and he was a co-founder and chair of its Area Committee on Molecular Methods from 1992 and 1998 to 2005, respectively. Dr. Enns has helped introduce approximately 35 different molecular diagnostic products and platforms through the in vitro diagnostic process at the Food and Drug Administration (FDA) since 1985, including infectious disease, oncology, and genetic tests.
Mark Gorman is Director of Survivorship Policy for the National Coalition for Cancer Survivorship (NCCS). He is a long-term survivor of metastatic melanoma. His work with NCCS focuses on advocacy for quality cancer care for all people touched by cancer. NCCS looks to the six aims of quality identified in Crossing the Quality Chasm for a framework for its advocacy. He has served on the EGAPP Stakeholders Group, the External Stakehold